ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Eco is not dead yet

Share On Facebook
share on Linkedin
Print

It was a tough half of the year for the green industry. According to the Institute of International Finance, ESG funds saw inflows halve in Q1 2022 amidst geopolitical tension and the energy crisis. ESG Q1 fund flows of $75 billion were at their lowest level in seven quarters. IIF data also showed that flows into ESG bonds were also down sharply in Q1, dropping to $14 billion from $27 billion.

The good news is that the fight against climate change is not over yet. Last week U.S. Senator Joe Manchin announced sudden support for Biden’s $739 billion “green bill.” The initiative is supposed to help the United States to reduce carbon emissions by about 40% by 2030. The funding is supposed to come from raising the corporate tax rate to 15% on corporations that make more than $1 billion a year.

The bill is set to provide $369 billion over a decade for climate change strategies, including investments in renewable energy production and tax credits for consumers to buy new or used electric cars. It also includes a $60 billion tax credit for clean energy production and a $30 billion tax credit for wind and solar energy production. In addition, there is a 10-year consumer tax credit for renewable energy investments.

The second part of the bill is directed at reducing the cost of prescription drugs. It is estimated that this initiative would save the federal government about $288 billion over a 10-year budget period. The bad news is that price controls could reduce biopharmaceutical industry revenues by $2.9 trillion through 2039 and threaten a sector that generates more than $1 trillion in economic activity annually. On top of that, the U.S. risks losing competitiveness to countries such as India and China.

Last but not least, President Biden needs the support of all 50 Democratic senators, as well as the deciding vote of Vice President Kamala Harris, to get the bill through the Senate and into the House. The Chips and Science (CHIP-plus) Act is the point at which climate, medical, and taxation issues will move forward.

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Plc. ADVFN Plc does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Leave A Reply

 
Do you want to write for our Newspaper? Get in touch: newspaper@advfn.com